The Lasers4Life clinical study keeps growing. The BIRD-Lasers4Life team is pleased to welcome two new clinical sites in Würzburg – the latest additions to a network of partners helping bring Infrared Molecular Fingerprinting (IMF) from the exploratory research toward everyday clinical practice.
This phase of the study is built around exactly that kind of growth – recruiting more clinical partners to strengthen enrolment for the lung cancer arm. It marks a deliberate step asking: Can Infrared Molecular Fingerprinting (IMF) support the clinical diagnosis of lung cancer, not just in a single setting, but wherever patients happen to be seen and samples collected?
The two new Würzburg sites will enroll both patients with therapy-naïve lung cancer and control participants. Each additional site brings its own patient mix and clinical routine – a fresh test of whether the method holds up.
Representatives of the study team at Klinikum Würzburg Mitte together with members of the BIRD-Lasers4Life team. Photo: L4L.
The team is grateful to the Bavarian Cancer Research Center (BZKF) for its continued support, and looks forward to welcoming many more participants in the months ahead.
Header Picture: Representatives of the study team at Universitätsklinikum Würzburg together with members of the BIRD-Lasers4Life team. Photo: L4L.
